PURPOSE: Data have suggested that the molecular features of breast cancer are important determinants of outcome; however, few studies have correlated these features with locoregional recurrence (LRR). In the present study, we evaluated estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) as predictors of LRR in patients with lymph node-negative disease and tumors < or = 1cm, because these patients often do not receive adjuvant chemotherapy or trastuzumab. METHODS AND MATERIALS: The data from 911 patients with stage T1a,bN0 breast cancer who had received definitive treatment at our institution between 1997 and 2002 were retrospectively reviewed. We prospectively analyzed ER/PR/HER2 expression from the archival tissue blocks of 756 patients. These 756 patients represented the cohort for the present study. RESULTS: With a median follow-up of 6.0 years, the 5- and 8-year Kaplan-Meier LRR rate was 1.6% and 5.9%, respectively, with no difference noted in those who underwent breast conservation therapy vs. mastectomy (p=.347). The 8-year LRR rates were greater in the patients with ER-negative (10.6% vs. 4.2%, p=.016), PR-negative (9.0% vs. 4.2%, p=.009), or HER2-positive (17.5% vs. 3.9%, p=0.009) tumors. On multivariate analysis, ER-negative and PR-negative disease (hazard ratio, 2.37; p=.046) and HER2-positive disease (hazard ratio, 3.13, p=.016) independently predicted for LRR. CONCLUSION: Patients with ER/PR-negative or HER2-positive T1a,bN0 breast cancer had a greater risk of LRR. Therapeutic strategies, such as the use of chemotherapy and/or anti-HER2 therapies, should be considered for future clinical trials for these patients. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: Data have suggested that the molecular features of breast cancer are important determinants of outcome; however, few studies have correlated these features with locoregional recurrence (LRR). In the present study, we evaluated estrogen receptor (ER), progesterone receptor (PR), and humanepidermal growth factor receptor 2 (HER2) as predictors of LRR in patients with lymph node-negative disease and tumors < or = 1cm, because these patients often do not receive adjuvant chemotherapy or trastuzumab. METHODS AND MATERIALS: The data from 911 patients with stage T1a,bN0 breast cancer who had received definitive treatment at our institution between 1997 and 2002 were retrospectively reviewed. We prospectively analyzed ER/PR/HER2 expression from the archival tissue blocks of 756 patients. These 756 patients represented the cohort for the present study. RESULTS: With a median follow-up of 6.0 years, the 5- and 8-year Kaplan-Meier LRR rate was 1.6% and 5.9%, respectively, with no difference noted in those who underwent breast conservation therapy vs. mastectomy (p=.347). The 8-year LRR rates were greater in the patients with ER-negative (10.6% vs. 4.2%, p=.016), PR-negative (9.0% vs. 4.2%, p=.009), or HER2-positive (17.5% vs. 3.9%, p=0.009) tumors. On multivariate analysis, ER-negative and PR-negative disease (hazard ratio, 2.37; p=.046) and HER2-positive disease (hazard ratio, 3.13, p=.016) independently predicted for LRR. CONCLUSION:Patients with ER/PR-negative or HER2-positive T1a,bN0 breast cancer had a greater risk of LRR. Therapeutic strategies, such as the use of chemotherapy and/or anti-HER2 therapies, should be considered for future clinical trials for these patients. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz Journal: Oncologist Date: 2011-12-06
Authors: Joachim Rom; Claudia Schumacher; Oleg Gluz; Josef Höfler; Sebastian Eidt; Christoph Domschke; Frederik Marmé; Ulrike Nitz; Christof Sohn; Andreas Schneeweiss Journal: Breast Care (Basel) Date: 2013-06 Impact factor: 2.860
Authors: Rachel L Theriault; Jennifer K Litton; Elizabeth A Mittendorf; Huiqin Chen; Funda Meric-Bernstam; Mariana Chavez-Macgregor; Phuong K Morrow; Wendy A Woodward; Aysegul Sahin; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Clin Breast Cancer Date: 2011-07-20 Impact factor: 3.225
Authors: Jona A Hattangadi-Gluth; Jennifer Y Wo; Paul L Nguyen; Rita F Abi Raad; Meera Sreedhara; Andrzej Niemierko; Phoebe E Freer; Dianne Georgian-Smith; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso Journal: Curr Treat Options Oncol Date: 2015-04
Authors: Abigail S Caudle; Kelly K Hunt; Henry M Kuerer; Funda Meric-Bernstam; Anthony Lucci; Isabelle Bedrosian; Gildy V Babiera; Rosa F Hwang; Merrick I Ross; Barry W Feig; Karen Hoffman; Jennifer K Litton; Aysegul A Sahin; Wei Yang; Gabriel N Hortobagyi; Thomas A Buchholz; Elizabeth A Mittendorf Journal: Ann Surg Oncol Date: 2011-09 Impact factor: 5.344